II. Indications: General

  1. Migraine Abortive Treatment
  2. Cluster Headache
  3. Controversial cohorts in whom Triptan use is now thought safe (Cardiovascular Risk Factors)
    1. Controlled Diabetes Mellitus
    2. Controlled Hypertension
    3. Controlled Hyperlipidemia
    4. Postmenopausal women
    5. Men over age 40 years

III. Contraindications

  1. Coronary Artery Disease
  2. Prinzmetal's Angina
  3. Uncontrolled Hypertension
  4. Basilar Artery Migraine
  5. Familial Hemiplegic Migraine
  6. Ischemic Cerebrovascular Accident
  7. Pregnancy
  8. Concurrent Medication use (absolute contraindications)
    1. MAO Inhibitor use
    2. Ergotamine use in prior 24 hours

IV. Mechanism

  1. Serotonergic 5-HT1 receptor Agonists
  2. Inhibits sensory dural nerve fiber neuropeptide release
  3. Intracranial extracerebral artery Vasoconstriction
    1. Mediated by Triptan direct effect on cerebrovascular Smooth Muscle

V. Dosing: General

  1. Screen for cardiovascular disease before use!
  2. Limit to no more than twice weekly

VI. Dosing: Sumatriptan (Imitrex)

  1. Subcutaneous Sumatriptan
    1. Initial: 6 mg SC
    2. Repeat in 12 hours prn
    3. Maximum: 12 mg/day
    4. Even generic dosing approaches $100/dose
  2. Oral Sumatriptan
    1. Dose 25 to 100 mg orally every 2 hours prn
      1. Start at max single dose, 100 mg orally for best efficacy in young adult without contraindications
    2. Maximum: 300 mg/day
    3. Generic dosing may be as low as $3/dose
  3. Intranasal Sumatriptan
    1. Initial: 5, 10 or 20 mg intranasal
      1. Dose responsive (20 mg more effective)
    2. Repeat after 2 hours prn
    3. Maximum: 40 mg/day
    4. Safety of use in over 4 Headaches per month not known
  4. Treximet (combination with Naproxen)
    1. Contains Sumatriptan 85 mg with Naproxen 500 mg
    2. Released as Sumatriptan becomes generically available
    3. Cheaper to purchase generic Sumatriptan (when available) and Naproxen separately
  5. Other Sumatriptan formulations
    1. Zecurity patch
      1. Removed from market 2016 due to serious adverse effects including burns
      2. http://www.fda.gov/Drugs/DrugSafety/ucm504588.htm

VII. Dosing: Rizatriptan (Maxalt, Maxalt MLT)

  1. Initial: 5 to 10 mg orally (MLT form is lingual)
    1. Start at max single dose, 10 mg orally for best efficacy in young adult without contraindications
  2. Repeat dose in 2 hours
  3. Maximum: 30 mg in 24 hours

VIII. Dosing: Naratriptan (Amerge)

  1. Initial: 1 to 2.5 mg orally
  2. Repeat in 4 hours
  3. Maximum: 5 mg in 24 hours
  4. Generic options available, but more expensive than Sumatriptan, Rizatriptan
  5. Consider for longer lasting Migraines (but have delayed onset)

IX. Dosing: Zolmitriptan (Zomig)

  1. Oral
    1. Initial: 1.25 to 2.5 mg orally
    2. Repeat dose every 2 hours
    3. Maximum: 10 mg in 24 hours
  2. Intranasal
    1. Dose: 5 mg spray (single dose unit)
    2. Onset: 15 minutes (faster than oral preparations)

X. Dosing: Eletriptan (Relpax)

  1. Initial: 20 to 40 mg orally
  2. May repeat dose in 2 hours
  3. Maximum: 40 mg/dose or 80 mg/day

XI. Dosing: Almotriptan (Axert)

  1. Initial: 6.25 to 12.5 mg orally; may repeat in 2 hours
  2. Maximum: 2 doses in 24 hours

XII. Dosing: Frovatriptan (Frova)

  1. Initial dosing: 2.5 mg orally; may repeat in 2 hours
  2. Maximum dose: 7.5 mg per day
  3. Consider for longer lasting Migraines (but have delayed onset)

XIII. Adverse Effects

  1. See Triptan Overdose
  2. Vasospasm
    1. Generally benign in low risk populations
    2. Avoid in Coronary Artery Disease, Cerebrovascular Disease, Peripheral Arterial Disease
    3. Also avoid in hemiplegic Migraine or basilar Migraine
  3. Medication Overuse Headaches
    1. Highest risk with >10 doses per month
    2. Limit to two doses weekly
  4. Injection (e.g. Sumatriptan)
    1. Tingling, Flushing or burning Sensation at injection sites
  5. Intranasal preparations
    1. Dysgeusia (Terrible taste)

XIV. Safety

  1. Unknown safety in Lactation
  2. Pregnancy Category C (most Triptans, but generally avoided in pregnancy)
    1. See Migraine Medications in Pregnancy
    2. Not recommended for routine use in pregnancy
    3. Consult obstetrics before use
    4. May be considered if Migraines are uncontrolled, debilitating
      1. If used, Sumatriptan has the longest safety data
    5. Adverse effects in pregnancy
      1. Avoid in first trimester (fetal malformations and adverse pregnancy outcomes)
      2. Risk of uterine atony and peripartum Hemorrhage (but may be considered in debilitating Headache)
      3. Associated with hyperactivity and emotionality at age 3 in exposed children (AHRQ)
    6. References
      1. Nezvalova-Henriksen (2010) Headache 50(4): 563-75 +PMID: 20132339 [PubMed]

XV. Drug Interactions

  1. See absolute contraindications above
    1. Ergotamine
    2. MAO Inhibitors
  2. Lithium
  3. Selective Serotonin Reuptake Inhibitor (SSRI)
    1. Risk of Serotonin Syndrome when combined with SSRI, SNRI or MAO Inhibitors
  4. Propranolol with Rizatriptan
    1. Requires reducing Rizatriptan dose

XVI. Efficacy: General

  1. Most effective oral agents (compared with Imitrex 100 mg PO)
    1. Rizatriptan (Maxalt) 10 mg orally
    2. Eletriptan (Relpax) 80 mg orally
    3. Almotriptan (Axert) 12.5 mg orally (least side effects)
  2. References
    1. Ferrari (2001) Lancet 358:1668-75 [PubMed]

XVII. Efficacy: Sumatriptan

  1. Efficacy dependent on mode of drug delivery
    1. Subcutaneous effective in 80% of patients
    2. Intranasal effective in 70% of patients
    3. Oral effective in 60% of patients
  2. Oral form does not prevent Migraine recurrence
    1. Rapoport (1995) Neurology 45:1505-9 [PubMed]

XVIII. Management: Overdose or Toxicity

XIX. Resources

  1. Triptans (StatPearls)
    1. https://www.ncbi.nlm.nih.gov/books/NBK554507/
  2. Where do Triptans act in the treatment of Migraine? (PMC)
    1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1850935/

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Serotonin 5-HT1 Receptor Agonists (C0162754)

Definition (MSH) Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.
Concepts Pharmacologic Substance (T121)
MSH D058825
SnomedCT 108405004, 363560004
English Serotonin 5-HT1 receptor agonist (substance), Serotonin 5-HT1 receptor agonist product (product), Serotonin 5-HT1 receptor agonist product (substance), Serotonin 5-HT1 receptor agonist product, Serotonin 5-HT1 receptor agonist, Serotonin 5-HT<sub>1</sub> receptor agonist (substance), Serotonin 5-HT<sub>1</sub> receptor agonist product (product), Serotonin 5-HT<sub>1</sub> receptor agonist product (substance), Serotonin 5-HT<sub>1</sub> receptor agonist product, Serotonin 5-HT<sub>1</sub> receptor agonist, Serotonin 5 HT1 Receptor Agonists, 5 HT1 Agonist, Agonists, 5-HT1, 5 HT1 AGON, 5 HT1 AG, 5-HT1 Agonists, 5-HT1 Agonist, Agonist, 5-HT1, Serotonin 5-HT1 Receptor Agonists, 5 HT1 Agonists, Serotonin 5-HT>1< receptor agonist (substance), Serotonin 5-HT>1< receptor agonist product (product), Serotonin 5-HT>1< receptor agonist product, Serotonin 5-HT>1< receptor agonist, Serotonin 5-HT>1< receptor agonist product (substance)
Spanish agonista del receptor de serotonina 5-HT<sub>1</sub> (sustancia), agonista del receptor de serotonina 5-HT<sub>1</sub>, agonista del receptor de serotonina 5-HT1 (sustancia), agonista del receptor de serotonina 5-HT1, Agonistas del Receptor de Serotonina 5-HT1, Agonistas de 5-HT1, agonista del receptor de serotonina 5-HT>1< (sustancia), agonista del receptor de serotonina 5-HT>1<, agonista del receptor serotoninérgico 5 - HT1, producto (producto), agonista del receptor serotoninérgico 5 - HT1, producto
French Agonistes 5-HT1, Agonistes des récepteurs 5-HT1 de la sérotonine
German 5-HT1-Agonisten, Serotonin-5-HT1-Rezeptor-Agonisten, Serotonin-5-HT1-Rezeptoragonisten, 5-HT1-Agonist
Czech 5-HT1 agonisté, serotoninové receptory 5-HT1 - agonisté
Italian Agonisti 5-HT1, Agonisti della serotonina 5-HT1, Agonista 5-HT1
Russian СЕРОТОНИНА 5-HT1 РЕЦЕПТОРОВ АГОНИСТЫ, SEROTONINA 5-HT1 RETSEPTOROV AGONISTY
Portuguese Agonistas do Receptor 5-HT1 de Serotonina, Agonista de 5-HT1, Agonista 5-HT1
Polish Agoniści receptora serotoninowego 5-HT1

Ontology: Triptans (C1567966)

Definition (MSH) Derivatives of TRYPTAMINES that are SEROTONIN RECEPTOR AGONISTS acting at 5-HT1 RECEPTORS. Some are used to treat MIGRAINE DISORDERS.
Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH D014363
French Triptans
Czech triptany
Norwegian Triptaner
English Triptans

Ontology: selective 5-HT receptor agonists (C2224138)

Concepts Pharmacologic Substance (T121)
English selective 5-HT receptor agonists, selective 5-HT receptor agonists (medication)